230 related articles for article (PubMed ID: 33601323)
1. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
Pearson AD; DuBois SG; Buenger V; Kieran M; Stegmaier K; Bandopadhayay P; Bennett K; Bourdeaut F; Brown PA; Chesler L; Clymer J; Fox E; French CA; Germovsek E; Giles FJ; Bender JG; Hattersley MM; Ludwinski D; Luptakova K; Maris J; McDonough J; Nikolova Z; Smith M; Tsiatis AC; Vibhakar R; Weiner S; Yi JS; Zheng F; Vassal G
Eur J Cancer; 2021 Mar; 146():115-124. PubMed ID: 33601323
[TBL] [Abstract][Full Text] [Related]
2. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
[TBL] [Abstract][Full Text] [Related]
3. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.
Pearson ADJ; Rossig C; Lesa G; Diede SJ; Weiner S; Anderson J; Gray J; Geoerger B; Minard-Colin V; Marshall LV; Smith M; Sondel P; Bajars M; Baldazzi C; Barry E; Blackman S; Blanc P; Capdeville R; Caron H; Cole PD; Jiménez JC; Demolis P; Donoghue M; Elgadi M; Gajewski T; Galluzzo S; Ilaria R; Jenkner A; Karres D; Kieran M; Ligas F; Lowy I; Meyers M; Oprea C; Peddareddigari VGR; Sterba J; Stockman PK; Suenaert P; Tabori U; van Tilburg C; Yancey T; Weigel B; Norga K; Reaman G; Vassal G
Eur J Cancer; 2020 Mar; 127():52-66. PubMed ID: 31986450
[TBL] [Abstract][Full Text] [Related]
4. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
Pearson ADJ; Barry E; Mossé YP; Ligas F; Bird N; de Rojas T; Zimmerman ZF; Wilner K; Woessmann W; Weiner S; Weigel B; Venkatramani R; Valteau D; Trahair T; Smith M; Singh S; Selvaggi G; Scobie N; Schleiermacher G; Richardson N; Park J; Nysom K; Norga K; Merino M; McDonough J; Matloub Y; Marshall LV; Lowe E; Lesa G; Irwin M; Karres D; Gajjar A; Doz F; Fox E; DuBois SG; Donoghue M; Casanova M; Caron H; Buenger V; Bradford D; Blanc P; Barone A; Reaman G; Vassal G
Eur J Cancer; 2021 Nov; 157():198-213. PubMed ID: 34536944
[TBL] [Abstract][Full Text] [Related]
5. Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson ADJ; Federico S; Gatz SA; Ortiz M; Lesa G; Scobie N; Gounaris I; Weiner SL; Weigel B; Unger TJ; Stewart E; Smith M; Slotkin EK; Reaman G; Pappo A; Nysom K; Norga K; McDonough J; Marshall LV; Ludwinski D; Ligas F; Karres D; Kool M; Horner TJ; Henssen A; Heenen D; Hawkins DS; Gore L; Bender JG; Galluzzo S; Fox E; de Rojas T; Davies BR; Chakrabarti J; Carmichael J; Bradford D; Blanc P; Bernardi R; Benchetrit S; Akindele K; Vassal G
Eur J Cancer; 2023 Sep; 190():112950. PubMed ID: 37441939
[TBL] [Abstract][Full Text] [Related]
6. Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson ADJ; Zwaan CM; Kolb EA; Karres D; Guillot J; Kim SY; Marshall L; Tasian SK; Smith M; Cooper T; Adamson PC; Barry E; Benettaib B; Binlich F; Borgman A; Brivio E; Capdeville R; Delgado D; Faller D; Fogelstrand L; Fraenkel PG; Hasle H; Heenen D; Kaspers G; Kieran M; Klusmann JH; Lesa G; Ligas F; Mappa S; Mohamed H; Moore A; Morris J; Nottage K; Reinhardt D; Scobie N; Simko S; Winkler T; Norga K; Reaman G; Vassal G
Eur J Cancer; 2020 Sep; 136():116-129. PubMed ID: 32688206
[TBL] [Abstract][Full Text] [Related]
7. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
8. Targeting BET bromodomain proteins in solid tumors.
Sahai V; Redig AJ; Collier KA; Eckerdt FD; Munshi HG
Oncotarget; 2016 Aug; 7(33):53997-54009. PubMed ID: 27283767
[TBL] [Abstract][Full Text] [Related]
9. Implementation of mechanism of action biology-driven early drug development for children with cancer.
Pearson AD; Herold R; Rousseau R; Copland C; Bradley-Garelik B; Binner D; Capdeville R; Caron H; Carleer J; Chesler L; Geoerger B; Kearns P; Marshall LV; Pfister SM; Schleiermacher G; Skolnik J; Spadoni C; Sterba J; van den Berg H; Uttenreuther-Fischer M; Witt O; Norga K; Vassal G;
Eur J Cancer; 2016 Jul; 62():124-31. PubMed ID: 27258969
[TBL] [Abstract][Full Text] [Related]
10. ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children.
Pearson ADJ; Scobie N; Norga K; Ligas F; Chiodin D; Burke A; Minard-Colin V; Adamson P; Marshall LV; Balakumaran A; Benettaib B; Bhargava P; Bollard CM; Bolotin E; Bomken S; Buechner J; Burkhardt B; Caron H; Copland C; Demolis P; Egorov A; Farhan M; Zugmaier G; Gross T; Horton-Taylor D; Klapper W; Lesa G; Marcus R; Miles RR; Nottage K; Pacaud L; Ricafort R; Schrappe M; Sterba J; Vezan R; Weiner S; Kim SY; Reaman G; Vassal G
Eur J Cancer; 2019 Mar; 110():74-85. PubMed ID: 30772656
[TBL] [Abstract][Full Text] [Related]
11. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
[TBL] [Abstract][Full Text] [Related]
12. Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Gaspar N; Janeway K; Campbell-Hewson Q; Lawlor ER; Copland C; Karres D; Norga K; Benzaghou F; Weiner S; Weigel B; Weiss AR; Strauss SJ; Smith M; Setty BA; Seibel N; Scobie N; Pappo A; Okpara CE; Nysom K; McDonough J; Marshall LV; Ludwinski D; Ligas F; Lesa G; Knudsen S; Kauh J; Hsieh A; Heenen D; Hawkins DS; Graham A; Garmey E; DuBois SG; Fox E; Donoghue M; de Rojas T; Chung J; Casanova M; Brennan B; Bishop M; Buenger V; Reaman G; Vassal G
Eur J Cancer; 2022 Sep; 173():71-90. PubMed ID: 35863108
[TBL] [Abstract][Full Text] [Related]
13. Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Allen C; Fangusaro J; Hutter C; Witt O; Weiner S; Reaman G; Russo M; Bandopadhayay P; Ahsan S; Barone A; Barry E; de Rojas T; Fisher M; Fox E; Bender JG; Gore L; Hargrave D; Hawkins D; Kreider B; Langseth AJ; Lesa G; Ligas F; Marotti M; Marshall LV; Nasri K; Norga K; Nysom K; Pappo A; Rossato G; Scobie N; Smith M; Stieglitz E; Weigel B; Weinstein A; Viana R; Karres D; Vassal G
Eur J Cancer; 2022 Dec; 177():120-142. PubMed ID: 36335782
[TBL] [Abstract][Full Text] [Related]
14. BET inhibitors: a novel epigenetic approach.
Doroshow DB; Eder JP; LoRusso PM
Ann Oncol; 2017 Aug; 28(8):1776-1787. PubMed ID: 28838216
[TBL] [Abstract][Full Text] [Related]
15. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.
Stathis A; Zucca E; Bekradda M; Gomez-Roca C; Delord JP; de La Motte Rouge T; Uro-Coste E; de Braud F; Pelosi G; French CA
Cancer Discov; 2016 May; 6(5):492-500. PubMed ID: 26976114
[TBL] [Abstract][Full Text] [Related]
16. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
17. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
Moreno L; Barone G; DuBois SG; Molenaar J; Fischer M; Schulte J; Eggert A; Schleiermacher G; Speleman F; Chesler L; Geoerger B; Hogarty MD; Irwin MS; Bird N; Blanchard GB; Buckland S; Caron H; Davis S; De Wilde B; Deubzer HE; Dolman E; Eilers M; George RE; George S; Jaroslav Š; Maris JM; Marshall L; Merchant M; Mortimer P; Owens C; Philpott A; Poon E; Shay JW; Tonelli R; Valteau-Couanet D; Vassal G; Park JR; Pearson ADJ
Eur J Cancer; 2020 Sep; 136():52-68. PubMed ID: 32653773
[TBL] [Abstract][Full Text] [Related]
18. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H
Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924
[TBL] [Abstract][Full Text] [Related]
19. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
20. Bromodomains: a new target class for drug development.
Cochran AG; Conery AR; Sims RJ
Nat Rev Drug Discov; 2019 Aug; 18(8):609-628. PubMed ID: 31273347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
